EUVIMEDEUVIMED entdecken
Open Access

Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer

Shuanghui Chen iD, Linzhao Li, Haohua Yuan, Huan Gui, Quan Wan, Mengjiao Wang, Hang Lv, Chenglv Wang, Lan Zhu, Yingjie Nie, Xiangyan Zhang

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxae110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Shuanghui Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Guizhou University, Guiyang, China. Hauptthemen laut MEDLINE: Poly I-C, Dendritic Cells, Lung Neoplasms, Imidazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Laboratory of Respiratory Diseases, Guizhou Provincial Science and Technology Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immunotherapy has rapidly become a primary treatment option for many lung cancer patients because of its success in treating this prevalent and deadly disease. However, the success of immunotherapy relies on overcoming the immunosuppressive tumor microenvironment, making remodeling this environment a potential strategy for lung cancer therapy. Research suggests that Toll-like receptor (TLR) agonists can impede tumor growth by promoting the conversion of tumor-associated macrophages into an M1-like state or enhancing dendritic cell development. However, there is insufficient research on the combined use of TLR agonists for treating lung cancer.

Methods

In this study, we examined how TLR agonists such as resiquimod (R848) and poly(I:C) impact lung cancer treatment when used alone or in combination. In vitro, the regulatory functions and mechanisms of R848 and poly(I:C) were analyzed in primary macrophages, RAW264.7 cells, and primary dendritic cells (DCs). Tumor treatment efficacy was assessed in vivo with a Lewis lung carcinoma (LLC) mouse model.

Results

The combination of R848 + poly(I:C) enhances the transformation of macrophages from the M2 phenotype to the M1 phenotype by increasing inflammatory cytokine levels. The percentage of mature DCs expressing MHC-II+CD11c+ and CD86+ cells was significantly higher in the R848 + poly(I:C) group compared with the other groups. Intratumoral injection of the synergistic combination of R848 + poly(I:C) suppressed tumor growth by increasing the M1:M2 ratio in TAMs, activating DCs, and attracting CD4+ and CD8+ T cells.

Conclusion

R848 + poly(I:C) synergistically induces M1-like polarization of macrophages, activates DCs, and promotes effective antitumor immunity in mice with subcutaneous LLC tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly I-CDendritic CellsLung NeoplasmsImidazolesCarcinoma, Lewis LungMacrophagesAnimalsMiceMice, Inbred C57BLTumor MicroenvironmentRAW 264.7 CellsImmunotherapyInjections, IntralesionalFemaleTumor-Associated MacrophagesCell Line, TumorDrug Synergism

Stichwörter der Autor:innen

cancerdendritic cellsimmunotherapymacrophage

Substanzen

Poly I-CresiquimodImidazoles

Autor:innen und Institutionen

  • School of Medicine, Guizhou University, Guiyang, China.
  • School of Basic Medical Sciences, Zunyi Medical University, Zunyi, China.
  • NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, China.

ORCID-Profile: Shuanghui Chen

Förderung

  • National Natural Science Foundation of China
  • National Key Laboratory of Respiratory Diseases
  • Guizhou Provincial Science and Technology Projects
  • Guizhou Immunotherapy Research Talent Base
  • Central Research Institute Fund of Chinese Academy of Medical Sciences

Zitieren

APA

Chen, S., Li, L., Yuan, H., Gui, H., Wan, Q., Wang, M., Lv, H., Wang, C., Zhu, L., Nie, Y., & Zhang, X. (2025). Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae110

Vancouver

Chen S, Li L, Yuan H, Gui H, Wan Q, Wang M, et al. Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae110

BibTeX
@article{Chen2025,
  author = {Chen, Shuanghui and Li, Linzhao and Yuan, Haohua and Gui, Huan and Wan, Quan and Wang, Mengjiao and Lv, Hang and Wang, Chenglv and Zhu, Lan and Nie, Yingjie and Zhang, Xiangyan},
  title = {Intratumoral injection of R848 and poly(I:C) synergistically promoted antitumor immune responses by reprogramming macrophage polarization and activating DCs in lung cancer},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxae110}
}
Kostenlos starten →